Literature DB >> 3034624

Aberrant expression of Ia-like antigens on tumor cells of regressing but not of progressing Rous sarcomas.

P C Powell, K Hála, G Wick.   

Abstract

Unlike many other tumors, experimentally induced Rous sarcomas in chickens have a definite tendency to regress spontaneously. Regression is under genetic control, but it is immunologically mediated although the target antigens that stimulate an immune response are unknown. Tumor cells in regressing sarcomas were found to express class II major histocompatibility complex (Ia-like) antigens while tumor cells from progressing sarcomas were negative. This suggests that the induction of Ia-like antigen expression has a role in the initiation or perpetuation of regression, similar to that postulated for class II antigen expression in a variety of autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3034624     DOI: 10.1002/eji.1830170523

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  5 in total

1.  Modulation of MHC antigen expression by viruses and oncogenes.

Authors:  D J Maudsley; J D Pound
Journal:  Immunol Today       Date:  1991-12

Review 2.  Genetic organization of the chicken MHC.

Authors:  G Kroemer; F Guillemot; C Auffray
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

3.  Regulation of IFN-gamma-induced host cell MHC antigen expression by Kirsten MSV and MLV. II. Effects on class II antigen expression.

Authors:  D J Maudsley; A G Morris
Journal:  Immunology       Date:  1989-05       Impact factor: 7.397

4.  Reduced stimulation of helper T cells by Ki-ras transformed cells.

Authors:  D J Maudsley; W J Bateman; A G Morris
Journal:  Immunology       Date:  1991-02       Impact factor: 7.397

5.  Major histocompatibility complex class II antigen expression during potentiation of line-10 tumor immunity after intralesional administration of bacillus Calmette-Guérin.

Authors:  P A Steerenberg; W H De Jong; E Geerse; B J Aleva; C M Besselink; B T Van Rens; V P Rutten; L G Poels; R J Scheper; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.